SCHEMBL3075110

SCHEMBL3075110

O[C@@H](c1c2ccccc2cc2ccccc12)C(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
HSD17B10 Q99714 2/20 0.39
CYP1A2 P05177 2/20 0.39
KDM4E B2RXH2 2/20 0.39
HPGD P15428 2/20 0.39
GLA P06280 1/20 0.39
CYP2C19 P33261 1/20 0.39
TRPM4 Q8TD43 1/20 0.38
PTPN1 P18031 1/20 0.38
HIF1A Q16665 1/20 0.37
CYP1B1 Q16678 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
HTR2A P28223 1/20 0.36
NQO2 P16083 1/20 0.36
DHODH Q02127 1/20 0.36
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35
PKM P14618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2482183 1.00 ALDH1A1 (0.39) ALDH1A1MEN1KMT2AHSD17B10CYP1A2
SCHEMBL977301 1.00 ALDH1A1 (0.39) ALDH1A1MEN1KMT2AHSD17B10CYP1A2
SCHEMBL8745296 0.87 ALDH1A1 (0.36) ALDH1A1MEN1KMT2AHSD17B10CYP1A2
SCHEMBL14155951 0.85 MEN1 (0.37) ALDH1A1MEN1KMT2AHSD17B10CYP1A2
SCHEMBL7074543 0.79 PTPN22 (0.47) ALDH1A1MEN1KMT2AHSD17B10CYP1A2
SCHEMBL29946603 0.79 PTPN22 (0.47) ALDH1A1MEN1KMT2AHSD17B10CYP1A2
SCHEMBL27925964 0.79 L3MBTL1 (0.37) ALDH1A1MEN1KMT2AHSD17B10CYP1A2
SCHEMBL14294943 0.78 DHODH (0.32) PTPN1DHODH
SCHEMBL10132729 0.78 DHODH (0.32) PTPN1DHODH
SCHEMBL488964 0.76 ALDH1A1 (0.46) ALDH1A1MEN1KMT2AHSD17B10CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11760750-B1 Process for preparing levoketoconazole NURAY CHEMICALS PRIVATE LIMITED (IN) 2023-09-19 US claimed
EP-1299342-B1 METHOD FOR PRODUCING 3,3-DIARYLPROPYLAMINES SANOL ARZNEI SCHWARZ GMBH (DE) 2007-05-02 EP claimed
CN-1269793-C Process for producing 3, 3-diarylpropylamines SANOL ARZNEI SCHWARZ GMBH (DE) 2006-08-16 CN claimed
US-6809225-B2 BY HYDROCARBONYLATION/HYDROFORMYLATION WITH SUBSEQUENT REDUCTIVE AMINATION SCHWARZ PHARMA AG (DE) 2004-10-26 US claimed
US-20040034080-A1 Method for producing 3,3-diarylpropylamines UCB PHARMA GMBH (DE) 2004-02-19 US claimed
CN-1441771-A Process for producing 3, 3-diarylpropylamines SANOL ARZNEI SCHWARZ GMBH (DE) 2003-09-10 CN claimed
EP-1299342-A1 METHOD FOR PRODUCING 3,3-DIARYLPROPYLAMINES SCHWARZ PHARMA AG (DE) 2003-04-09 EP claimed
WO-2002004399-A1 METHOD FOR PRODUCING 3,3-DIARYLPROPYLAMINES SCHWARZ PHARMA AG (DE) 2002-01-17 WO claimed
WO-2023173359-A1 METABOLIC DISEASE THERAPEUTIC AGENT OR PREVENTIVE AGENT 北京大学 2023-09-21 WO disclosed
US-11760750-B1 Process for preparing levoketoconazole NURAY CHEMICALS PRIVATE LIMITED (IN) 2023-09-19 US disclosed
EP-3438113-B1 TETRADENTATE LIGAND, AND PRODUCTION METHOD THEREFOR, SYNTHETIC INTERMEDIATE THEREOF, AND TRANSITION METAL COMPLEX THEREOF TAKASAGO PERFUMERY CO LTD (JP) 2021-02-17 EP disclosed
US-10731062-B2 Gas-generating material and micropump SEKISUI CHEMICAL CO., LTD. (JP) 2020-08-04 US disclosed
EP-2860167-B1 GAS GENERATING MATERIAL, AND MICROPUMP SEKISUI CHEMICAL CO LTD (JP) 2020-04-29 EP disclosed
US-10550141-B2 Tetradentate ligand, and production method therefor, synthetic intermediate thereof, and transition metal complex thereof TAKASAGO INTERNATIONAL CORPORATION (JP) 2020-02-04 US disclosed
WO-1991011449-A1 PROCESS FOR THE PRODUCTION OF THIENOTRICYCLENE BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1991-08-08 WO disclosed
US-5004754-A Biofungicidal composition UNIVERSITE LAVAL (CA) 1991-04-02 US disclosed
EP-0403252-A2 Process for preparation of epoxy esters and intermediates prepared thereby SMITHKLINE BEECHAM CORPORATION (US) 1990-12-19 EP disclosed
US-4950761-A Anticarcinogenic agent SOUTHERN RESEARCH INSTITUTE (US) 1990-08-21 US disclosed
EP-0336345-A2 (2S)-(5-Amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl)-carbamic acid, ethyl ester Southern Research Institute (US) 1989-10-11 EP disclosed
US-4866059-A ANTICARCINOGENIC AGENTS; FUNGICIDES WARNER-LAMBERT COMPANY (US) 1989-09-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034080-A1 Method for producing 3,3-diarylpropylamines HNMT, CYP1A1, HRH3 ALDH1A1 121/4885MEN1 1298/4885KMT2A 207/4885
US-10550141-B2 Tetradentate ligand, and production method therefor, synthetic intermediate thereof, and transition metal complex thereof CYP4F11, SLC39A11, CYP51A1 ALDH1A1 970/4885MEN1 337/4885KMT2A 2986/4885
US-11760750-B1 Process for preparing levoketoconazole KHK, KYAT3, PLK3 ALDH1A1 2659/4885MEN1 2073/4885KMT2A 1550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.